SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.

Journal: Cell
Published:
Abstract

SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we evaluated the T cell receptor sequences and phenotype of lymph node TFH. Mining of the responding TFH T cell receptor repertoire revealed a strikingly immunodominant HLA-DPB1∗04-restricted response to S167-180 in individuals with this allele, which is among the most common HLA alleles in humans. Paired blood and lymph node specimens show that while circulating S-specific TFH cells peak one week after the second immunization, S-specific TFH persist at nearly constant frequencies for at least six months. Collectively, our results underscore the key role that robust TFH cell responses play in establishing long-term immunity by this efficacious human vaccine.

Authors
Philip Mudd, Anastasia Minervina, Mikhail Pogorelyy, Jackson Turner, Wooseob Kim, Elizaveta Kalaidina, Jan Petersen, Aaron Schmitz, Tingting Lei, Alem Haile, Allison Kirk, Robert Mettelman, Jeremy Crawford, Thi H Nguyen, Louise Rowntree, Elisa Rosati, Katherine Richards, Andrea Sant, Michael Klebert, Teresa Suessen, William Middleton, Sharlene Teefey, Jane O'halloran, Rachel Presti, Katherine Kedzierska, Jamie Rossjohn, Paul Thomas, Ali Ellebedy